Apellis Pharmaceuticals SG&A Expense (Quarterly) Analysis

Apellis Pharmaceuticals Inc (APLS)

49.93 +1.21 (+2.48%) USD | NASDAQ | Apr 24, 16:00

49.86 -0.07 (-0.14%) After-Hours: 20:00

SG&A Expense (Quarterly) Chart

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2014. Upgrade now.

Date	Value
December 31, 2023	141.70M
September 30, 2023	145.65M
June 30, 2023	111.37M
March 31, 2023	102.09M
December 31, 2022	84.37M
September 30, 2022	78.41M
June 30, 2022	63.20M
March 31, 2022	51.19M
December 31, 2021	41.46M
September 30, 2021	45.76M
June 30, 2021	48.97M
March 31, 2021	40.58M
December 31, 2020	44.49M
September 30, 2020	36.99M
June 30, 2020	28.41M
March 31, 2020	29.50M
December 31, 2019	27.47M

Date	Value
September 30, 2019	18.63M
June 30, 2019	12.78M
March 31, 2019	8.171M
December 31, 2018	6.391M
September 30, 2018	6.265M
June 30, 2018	5.948M
March 31, 2018	4.035M
December 31, 2017	4.86M
September 30, 2017	2.071M
June 30, 2017	1.710M
March 31, 2017	1.821M
December 31, 2016	1.087M
September 30, 2016	1.000M
December 31, 2015	3.042M
September 30, 2015	1.413M
December 31, 2014	1.026M
September 30, 2014	0.6697M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

12.78M

Minimum

Jun 2019

145.65M

Maximum

Sep 2023

60.69M

Average

45.76M

Median

Sep 2021

SG&A Expense (Quarterly) Benchmarks